Role of matrix metalloproteinases in chronic rhinosinusitis

Current Opinion in Allergy and Clinical Immunology

Volumn 8, Issue 1, 2008, Pages 21-27

  Kostamo, Katriina ^a   Toskala, Elina ^b   Tervahartiala, Taina ^c,d   Sorsa, Timo ^c,d  

^a KYMENLAAKSO CENTRAL HOSPITAL   (Finland)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Chronic rhinosinusitis; Metalloproteinase; Nasal polyposis; Remodelling

Indexed keywords

COLLAGENASE; GELATINASE; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

CHRONIC SINUSITIS; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; NOSE POLYP; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHINOSINUSITIS;

CHRONIC DISEASE; EOSINOPHILS; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INFLAMMATION; MATRIX METALLOPROTEINASES; SINUSITIS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 38049169466     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3282f3f461     Document Type: Review

References (44)

1. Chen Y, Dales R, Lin M. The epidemiology of chronic rhinosinusitis in Canadians. Laryngoscope 2003; 113:1199-1205.
2. Kaliner MA, Osguthorpe JD, Fireman P, et al. Sinusitis: bench to bedside. Current findings, future directions. J Allergy Clin Immunol 1997; 99:S829-S848.
3. Bachert C, Patou J, Van Cauwenberge P. The role of sinus disease in asthma. Curr Opin Allergy Clin Immunol 2006; 6:29-36. This paper nicely summarizes the current evidence for the link between CRS and asthma, and also gives a hypothesis for the possible pathogenic mechanisms explaining this link.
4. Bousquet J, Jeffery PK, Busse WW, et al. Asthma. From bronchoconstriction to airways inflammation and remodelling. Am J Respir Crit Care Med 2000; 161:1720-1745.
5. Chiappara G, Gagliardo R, Siena A, et al. Airway remodelling in the pathogenesis of asthma. Curr Opin Allergy Clin Immunol 2001; 1:85-93.
6. Ponikau JU, Sherris DA, Kephart GM, et al. Features of airway remodeling and eosinophilic inflammation in chronic rhinosinusitis: is the histopathology similar to asthma? J Allergy Clin Immunol 2003; 112:877-882.
7. Polzehl D, Moeller P, Riechelmann H, Perner S. Distinct features of chronic rhinosinusitis with and without nasal polyps. Allergy 2006; 61:1275-1279. This histochemical study reports differences in inflammatory cell infiltration between the early stages of nasal polyposis and CRSsNP, suggesting that CRSwNP and CRSsNP represent two different disease entities.
8. Al-Rawi MM, Edelstein DR, Erlandson RA. Changes in nasal epithelium in patients with severe chronic sinusitis: a clinicopathologic and electron microscopic study. Laryngoscope 1998; 108:1816-1823.
9. Kelly EA, Jarjour NN. Role of matrix metalloproteinases in asthma. Curr Opin Pulm Med 2003; 9:28-33.
10. Gueders MM, Foidart JM, Noel A, Cataldo DD. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Eur J Pharmacol 2006; 533:133-144. This is a compact review about MMPs in asthma and other lung diseases with a good overview of the interaction between MMPs and other mediators, and how these interactions may contribute to the pathogenesis of asthma.
11. Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. Respir Res 2001; 2:10-19.
12. Greenlee KJ, Werb Z, Kheradmand F. Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev 2007; 87:69-98. This is an excellent and comprehensive review that explains the physiologic functions of MMPs in the lungs and the role of MMPs in inflammatory lung diseases.
13. Fokkens W, Lund V, Bachert C, et al. EAACI. European position paper on rhinosinusitis and nasal polyps. Rhinol Suppl 2005; 18:1-87.
14. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol 2004; 114:155-212.
15. Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 2006; 61:1280-1289. This study, with well-defined patient groups, demonstrates significant differences in the cellular and mediator profiles between polypoid and nonpolypoid CRS and questions the concept of nasal polyposis as a subcategory of CRS.
16. Jankowski R, Bouchoua F, Coffinet L, Vignaud JM. Clinical factors influencing the eosinophil infiltration of nasal polyps. Rhinology 2002; 40:173-178.
17. Hamilos DL, Leung DY, Huston DP, et al. GM-CSF, IL-5 and RANTES immunoreactivity and mRNA expression in chronic hyperplastic sinusitis with nasal polyposis (NP). Clin Exp Allergy 1998; 28:1145-1152.
18. Bachert C, Gevaert P, Holtappels G, et al. Nasal polyposis: from cytokines to growth. Am J Rhinol 2000; 14:279-290.
19. Minshall EM, Cameron L, Lavigne F, et al. Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. Am J Respir Cell Mol Biol 1997; 17:683-690.
20. Bachert C, Wagenmann M, Rudack C, et al. The role of cytokines in infectious sinusitis and nasal polyposis. Allergy 1998; 53:2-13.
21. Hamilos DL. Chronic sinusitis. J Allergy Clin Immunol 2000; 106:213-227.
22. Rinia AB, Kostamo K, Ebbens FA, et al. Nasal polyposis: a cellular-based approach to answering questions. Allergy 2007; 62:348-358. This review describes the interactions between epithelial cells and fibroblasts (epithelial-mesenchymal unit) in CRS.
23. Holgate ST, Davies DE, Lackie PM, et al. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol 2000; 105:193-204.
24. Pawankar R, Nonaka M. Inflammatory mechanisms and remodeling in chronic rhinosinusitis and nasal polyps. Curr Allergy Asthma Rep 2007; 7:202-208.
25. Molet SM, Hamid QA, Hamilos DL. IL-11 and IL-17 expression in nasal polyps: relationship to collagen deposition and suppression by intranasal fluticasone propionate. Laryngoscope 2003; 113:1803-1812.
26. Sobol SE, Fukakusa M, Christodoulopoulos P, et al. Inflammation and remodeling of the sinus mucosa in children and adults with chronic sinusitis. Laryngoscope 2003; 113:410-414.
27. Liu Z, Lu X, Wang H, et al. The up-regulated expression of tenascin Cin human nasal polyp tissues is related to eosinophil-derived transforming growth factor beta1. Am J Rhinol 2006; 20:629-633.
28. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92:827-839.
29. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378:151-160.
30. VanWart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 1990; 87:5578-5582.
31. Sorsa T, Tjaderhane L, Konttinen YT, et al. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med 2006; 38:306-321.
32. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999; 31:34-45.
33. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274:21491-21494.
34. Murphy G, Stanton H, Cowell S, et al. Mechanisms for pro matrix metalloproteinase activation. APMIS 1999; 107:38-44.
35. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74:111-122.
36. Hayakawa T, Yamashita K, Tanzawa K, et al. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992; 298:29-32.
37. Valente P, Fassina G, Melchiori A, et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998; 75:246-253.
38. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000; 14:2123-2133.
39. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007; 8:221-233.
40. Herouy Y. Matrix metalloproteinases in skin pathology. Int J Mol Med 2001; 7:3-12.
41. Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113:2089-2096.
42. Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001; 21:7724-7732.
43. Mix KS, Sporn MB, Brinckerhoff CE, et al. Novel inhibitors of matrix metalloproteinase gene expression as potential therapies for arthritis. Clin Orthop 2004; S129-S137.
44. McMillan SJ, Kearley J, Campbell JD, et al. Matrix metalloproteinase-9 deficiency results in enhanced allergen-induced airway inflammation. J Immunol 2004; 172:2586-2594.